Advertisement
Singapore markets close in 3 hours 13 minutes

  • Straits Times Index

    3,280.04
    -13.09 (-0.40%)
     

  • Nikkei

    37,640.13
    -819.95 (-2.13%)
     

  • Hang Seng

    17,274.38
    +73.11 (+0.43%)
     

  • FTSE 100

    8,040.38
    -4.43 (-0.06%)
     

  • Bitcoin USD

    64,292.01
    -2,445.09 (-3.66%)
     

  • CMC Crypto 200

    1,386.56
    -37.54 (-2.64%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • Dow

    38,460.92
    -42.77 (-0.11%)
     

  • Nasdaq

    15,712.75
    +16.11 (+0.10%)
     

  • Gold

    2,329.80
    -8.60 (-0.37%)
     

  • Crude Oil

    82.96
    +0.15 (+0.18%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • FTSE Bursa Malaysia

    1,570.29
    -1.19 (-0.08%)
     

  • Jakarta Composite Index

    7,157.23
    -17.30 (-0.24%)
     

  • PSE Index

    6,582.35
    +9.60 (+0.15%)
     

Actavis to buy Forest Labs in $25B deal

Actavis to buy Forest Labs in $25 billion cash-and-stock drugmaker combination

Associated Press

NEW YORK (AP) -- Actavis PLC says it will acquire fellow drugmaker Forest Laboratories Inc. in a cash-and-stock deal worth about $25 billion.

The deal would create a combined company spanning both generic and branded drugs, including Forest's Alzheimer's treatment Namenda and the antidepressant Lexapro.

Actavis will pay Forest shareholders $26.04 in cash and a portion of an Actavis share for each Forest share. The total, per-share price of $89.48 represents a premium of about 25 percent over Friday's closing price.

Dublin-based Actavis has grown rapidly through acquisition, including an $8.5 billion deal last year to buy another Irish drugmaker, Warner Chilcott.

New York-based Forest Labs has been squeezed by generic competition to some of its biggest drugs, including Lexapro. It has been working to cut costs under new CEO Brenton L. Saunders.